U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527169) titled 'A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma' on April 07.
Brief Summary: The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be studied.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Olfactory Neuroblastoma
Intervention:
DRUG: Zanzalintinib
Given orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....